Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd operates with a capital structure that shows a negative total equity of ₹250.25 million and a debt-to-equity ratio of -2.49, indicating a high reliance on debt financing and a weak equity position. The company’s liquidity is further constrained by a current ratio of 0.36, suggesting limited short-term liquidity to cover its immediate liabilities. Despite a net cash outflow, the company reported positive operating cash flow of ₹26.03 million, which may support near-term operational needs. Profitability metrics reveal significant challenges, with a net loss of ₹96.83 million and an operating loss of ₹110.80 million in the latest reporting period. The return on assets (ROA) is negative at -11.61%, and the return on equity (ROE) is 38.69%, which is misleading due to the negative equity base. These figures fall well below the typical performance of the pharmaceutical industry, where positive ROA and ROE are expected for sustainable operations. The company operates in a single segment focused on pharmaceuticals and APIs, with no disclosed geographic diversification in revenue. All operations are based in India, and the company sells products to related entities, suggesting a concentration risk in both revenue and customer base. There is no indication of geographic expansion or diversification in the financial or operational disclosures. Growth prospects appear limited, with no revenue growth reported in the latest period and a net loss continuing from prior periods. The company’s capital expenditure of ₹113.92 million was offset by negative free cash flow of ₹202.58 million, indicating that investments are not yet generating sufficient returns. There are no disclosed plans for new product launches or market expansion that would suggest a near-term turnaround. The company faces moderate liquidity risk due to its negative net cash position and high debt load, with a liquidity risk score of medium. The risk assessment also flags a negative net cash position after subtracting total debt, which could limit the company’s ability to meet long-term obligations. Dilution risk is currently low, as there is no indication of share issuance or dilution potential in the latest financials. No recent events, such as earnings calls, regulatory filings, or material business developments, are disclosed in the available data. The company’s financial performance and operational strategy remain largely unchanged in the latest reporting period.